Stock Events

Stock Events

Telomir Pharmaceuticals 

$1.32
0
+$0.07+5.6% Today

Statistics

Day High
1.32
Day Low
1.32
52W High
-
52W Low
-
Volume
2
Avg. Volume
-
Mkt Cap
45.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.08
-0.08
-0.07
-0.07
Expected EPS
-0.07
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-33.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TELO.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a major player in the pharmaceutical industry, directly competing with Telomir Pharmaceuticals in the development and marketing of drugs in similar therapeutic areas.
Merck
MRK
Mkt Cap298.84B
Merck operates in the same sectors as Telomir Pharmaceuticals, particularly in oncology and immunology, making them direct competitors.
Novartis
NVS
Mkt Cap297.32B
Novartis competes with Telomir Pharmaceuticals in multiple drug categories, including those for chronic diseases, which overlaps with Telomir's product lines.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences competes in the antiviral and oncology sectors, areas where Telomir Pharmaceuticals also aims to innovate.
AMGEN
AMGN
Mkt Cap187.56B
Amgen's focus on biologics and specialty drugs pits it directly against Telomir Pharmaceuticals in the biopharmaceutical market.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie's broad range of pharmaceutical products in immunology and oncology competes with Telomir's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb's extensive portfolio in cancer and cardiovascular diseases makes it a significant competitor to Telomir Pharmaceuticals.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly's strong presence in diabetes and cancer treatment areas competes with Telomir Pharmaceuticals' research and drug development.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson's large scale and diverse healthcare products, including pharmaceuticals, make it a formidable competitor across many of Telomir's key areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, known for its innovative biotechnology products, competes in the same biopharmaceutical niche as Telomir Pharmaceuticals.

About

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Show more...
CEO
ISIN
US87975F1049

Listings

XNAS
US
TELO
BOATS
BOATS
TELO.BOATS

0 Comments

Share your thoughts

FAQ

What is Telomir Pharmaceuticals stock price today?▼
The current price of TELO.BOATS is $1.32 USD — it has increased by +5.6% in the past 24 hours. Watch Telomir Pharmaceuticals stock price performance more closely on the chart.
What is Telomir Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telomir Pharmaceuticals stocks are traded under the ticker TELO.BOATS.
What is Telomir Pharmaceuticals market cap?▼
Today Telomir Pharmaceuticals has the market capitalization of 45.38M
When is the next Telomir Pharmaceuticals earnings date?▼
Telomir Pharmaceuticals is going to release the next earnings report on June 03, 2026.
What is Telomir Pharmaceuticals revenue for the last year?▼
Telomir Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Telomir Pharmaceuticals net income for the last year?▼
TELO.BOATS net income for the last year is -33.07M USD.
When did Telomir Pharmaceuticals complete a stock split?▼
Telomir Pharmaceuticals has not had any recent stock splits.